1.20
price down icon0.83%   -0.01
after-market アフターアワーズ: 1.21 0.01 +0.83%
loading
前日終値:
$1.21
開ける:
$1.19
24時間の取引高:
371.65K
Relative Volume:
0.57
時価総額:
$38.42M
収益:
-
当期純損益:
$-51.50M
株価収益率:
-0.30
EPS:
-4
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
-9.09%
1か月 パフォーマンス:
-18.37%
6か月 パフォーマンス:
-77.06%
1年 パフォーマンス:
-87.39%
1日の値動き範囲:
Value
$1.11
$1.21
1週間の範囲:
Value
$1.11
$1.31
52週間の値動き範囲:
Value
$0.87
$9.98

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
名前
Outlook Therapeutics Inc
Name
セクター
Healthcare (1162)
Name
電話
(609) 619-3990
Name
住所
111 S. WOOD AVENUE, ISELIN, NJ
Name
職員
23
Name
Twitter
Name
次回の収益日
2024-08-14
Name
最新のSEC提出書
Name
OTLK's Discussions on Twitter

OTLK を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.20 38.42M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-02 ダウングレード Chardan Capital Markets Buy → Neutral
2024-03-27 アップグレード BTIG Research Neutral → Buy
2024-02-15 アップグレード Chardan Capital Markets Neutral → Buy
2024-01-25 アップグレード Guggenheim Neutral → Buy
2023-12-27 アップグレード CapitalOne Equal Weight → Overweight
2023-08-31 ダウングレード Chardan Capital Markets Buy → Neutral
2023-08-31 ダウングレード H.C. Wainwright Buy → Neutral
2023-08-30 ダウングレード BTIG Research Buy → Neutral
2023-08-30 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-08-30 ダウングレード CapitalOne Overweight → Equal Weight
2023-08-30 ダウングレード Guggenheim Buy → Neutral
2023-07-13 開始されました CapitalOne Overweight
2023-04-03 開始されました Guggenheim Buy
2023-02-06 開始されました Cantor Fitzgerald Overweight
2022-10-31 開始されました BTIG Research Buy
2022-09-13 開始されました Chardan Capital Markets Buy
2019-09-11 開始されました Ladenburg Thalmann Buy
2019-05-16 開始されました Oppenheimer Outperform
2019-04-22 開始されました Ascendiant Capital Markets Buy
すべてを表示

Outlook Therapeutics Inc (OTLK) 最新ニュース

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025
pulisher
Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World

Feb 19, 2025
pulisher
Feb 19, 2025

Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Feb 18, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat

Feb 18, 2025
pulisher
Feb 16, 2025

ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 14, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire

Feb 14, 2025
pulisher
Feb 14, 2025

Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com

Feb 14, 2025

Outlook Therapeutics Inc (OTLK) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
大文字化:     |  ボリューム (24 時間):